QSI — Quantum-Si Incorporated

Is QSI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Strong Oversold As of November 17, 2026

Quantum-Si Incorporated (QSI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.06. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Quantum-Si Incorporated (QSI) is an early-stage instrument and platform company in proteomics with meaningful long-term upside if its single-molecule protein sequencing technology reaches commercial scale. Near-term fundamentals are dominated by limited revenue visibility and dependence on financing; sector signals around convertible-debt and dilution amplify shareholder risk. Execution and technical milestones (manufacturing scale, reproducible results, customer adoption) are the primary catalysts, while cash runway, capital markets access and competition are key constraints. Given current information gaps and low market liquidity, downside outcomes from financing or execution setbacks are a material probability over the coming month.

Key factors

  • Early-stage commercial profile with technology focused on single-molecule protein sequencing and instrument/platform commercialization potential
  • Limited or uneven near-term revenue visibility; financial health depends on cash runway and access to capital
  • High dilution risk for mid-cap diagnostics/biotech names amid sector convertible-debt financing trends
  • Large total addressable market in proteomics if platform achieves technical and pricing milestones
  • Low liquidity and high share-price volatility typical of micro-/small-cap life-science equipment developers
  • Market risk-on tone favors growth, but investors have been favoring larger, more defensive biopharma — limited sector tailwinds for a small-cap equipment developer
  • Sparse recent public filing and social sentiment data increases uncertainty around near-term catalysts

Risks

  • Short cash runway or need for dilutive capital raises that materially dilute existing shareholders
  • Execution risk in scaling manufacturing, achieving reproducible platform performance and commercialization timelines
  • Technical risk that single-molecule protein sequencing cannot be delivered at cost/throughput required for widescale adoption
  • Competitive pressure from established instrument and genomics players entering downstream proteomics
  • Low trading liquidity creating outsized price moves on limited news or block trades
  • Regulatory/commercial adoption delays from customers (labs, pharma) slowing revenue ramp
  • Macroeconomic tightening or a poor capital markets environment that raises financing costs or restricts access to non-dilutive capital

See today's live rating, score and targets

Members see the live hourly rating for QSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.